BOSTON : A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaMultiple Myeloma

Trial Overview Read MoreRead more

This trial evaluates the effectiveness, safety and affect on quality of life for two drug regimes using a combination of targeted therapy drugs (Selinexor, Bortezomib) and steroids (Dexamethasone) for the treatment of patients with recurrent Multiple Myeloma.
 

This trial is treating patients with Multiple Myeloma.

This is a systemic therapy.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Commercial Sponsor

Karyopharm Therapeutics, Inc

Summary

This study aims to assess effectiveness, safety and affect on quality of life for two drug regimes using a combination of targeted therapy drugs and corticosteroids to treat patients that have recurrent Multiple Myeloma and have previously undergone 1-3 treatments for Multiple Myeloma. Patients eligible to participate in this trial will receive either 5 doses of Selinexor, 4 doses of Bortezomib and 10 doses of Dexamthasone for each 35 day cycle, or 4 doses of Bortezomib and 8 doses of Dexamthasone for the first 8 x 21 day cycles.

Recruiting Hospitals Read MoreRead more

Alfred Hospital, Malignant Haematology & Stem Cell Transplantation Service
Prahran
Ms Nola Kennedy
n.kennedy@alfred.org.au
03 9076 2217

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next